Systemic delivery of RafsiRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer.
Raf-1, a protein serine-threonine kinase, plays a critical role in mitogen-activated protein kinase kinase (MKK/MEK)- mitogen-activated protein kinase (extracellular signal-regulated kinase) (MAPK/ERK) pathways. We show here that systemically delivered novel cationic cardiolipin liposomes (NeoPhectin-AT) containing a small interfering RNA (siRNA) against Raf-1 silence the expression of Raf-1 in tumor tissues and inhibit tumor growth in xenograft model of human prostate cancer. The knockdown of Raf-1 expression by siRNA is also associated with down-regulation of cyclin D1 expression in vivo.
Pal
Ajai
A
Pharmacokinetics, Safety and Efficacy Department, NeoPharm Inc., Research and Development, 1850 Lakeside Drive, Waukegan, IL 60085, USA.
Ahmad
Ateeq
A
Khan
Sumsullah
S
Sakabe
Isamu
I
Zhang
Chuanbo
C
Kasid
Usha N
UN
Ahmad
Imran
I
D002308:Cardiolipins / Q000494:pharmacology*; D002412:Cations; D019938:Cyclin D1 / Q000096:biosynthesis; D015536:Down-Regulation; D020868:Gene Silencing; D006801:Humans; D008081:Liposomes; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D019908:Proto-Oncogene Proteins c-raf / Q000096:biosynthesis*; D034622:RNA Interference; D034741:RNA, Small Interfering; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D002308:Cardiolipins; D002412:Cations; D008081:Liposomes; D034741:RNA, Small Interfering; D019938:Cyclin D1; D019908:Proto-Oncogene Proteins c-raf